Donor/recipient mixed chimerism does not predict graft failure in children with  -thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling

Lisini, Daniela; Zecca, Marco; Giorgiani, Giovanna; Montagna, Daniela; Cristantielli, Rosaria; Labirio, Massimo; Grignani, Pierangela; Previderé, Carlo; Cesare-Merlone, Alessandra Di; Amendola, Giovanni; Bergami, Elena; Mastronuzzi, Angela; Maccario, Rita; Locatelli, Franco

doi:10.3324/haematol.13248

Cited by 62 publications

(46 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, are T, B, or other lymphocyte subsets responsible for allowing this persistent and stable mixed chimerism? Lisini et al 18 performed a preliminary analysis in 13 patients within the first year after transplant, finding that the average percentage of donor cells was 75% (range, 30-90%) for leukocytes; 52% (range, 10-80%) for CD4 cells, 44% (range, 10-80%) for CD8 cells and 90% (range, 60-95%) for CD19 cells. In their patients, there was high number of B cells, with generally 10-20% fewer donor T cells.…”

Section: In Mixed Hematopoietic Chimerism the Donor Red Cells Winmentioning

confidence: 99%

In mixed hematopoietic chimerism, the donor red cells win

Hsieh¹,

Wu²,

Tisdale³

2010

Haematologica

View full text Add to dashboard Cite

Section: In Mixed Hematopoietic Chimerism the Donor Red Cells Winmentioning

confidence: 99%

In mixed hematopoietic chimerism, the donor red cells win

Hsieh¹,

Wu²,

Tisdale³

2010

Haematologica

View full text Add to dashboard Cite

“…In thalassemia transplantations, mixed chimerism was noted in 74% and 34% of recipients at 1 and 6 months, respectively; the incidence of secondary (late) graft rejection at 1 year after transplantation was only 8%. 41 Murine models of SCD suggest that normal erythrocytes have a survival advantage that may be based both on normal red cell longevity and effective erythropoiesis.…”

Section: Mixed Chimerism Is Acceptable In Nonmalignant Disordersmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: Current Practice and Emerging Trends

Shenoy

2011

Hematology

View full text Add to dashboard Cite

Allogeneic HSCT controls sickle cell disease (SCD)-related organ damage and is currently the only curative therapy available. Over the last 2 decades, HSCT has been limited largely to myeloablative matched sibling donor (MSD) procedures that are feasible only in a minority of patients. As the natural history of the disease has evolved, it is clear that subsets of patients with severe disease are at risk for sudden death, devastating CNS and pulmonary complications, and debilitating vasoocclusive crises. For these patients, the benefits of transplantation can outweigh the risks if HSCT can be safely and successfully performed with low early and late toxicities. This review describes advances and ongoing investigation of HSCT for SCD from the perspectives of recipient age and presentation, donor stem cell source, intensity of conditioning, family and medical perspectives, and other variables that influence outcome. Ultimately, HSCT should be viewed as a viable treatment option for SCD on par with other therapies for select patients who can benefit from the procedure.

show abstract

“…5 Moreover, different from what was observed by the Locatelli group in HLA identical sibling cord blood settings, we have shown that in β-Thal patients, after bone marrow transplantation, in order to obtain a durable complete or mixed chimerism an early engraftment of donor-derived cells larger than 90% is necessary. [6][7][8] Therefore graft rejection probabilities were higher in patients with MC detected within the first months after the transplant and proportional to the amount 1 regulatory cells are associated with PMC and may play an important role in sustaining long-term tolerance in vivo. 11 Up to now, it is not clear if the mechanisms inducing an immunological tolerance in patients with PMC might also influence a different maturation of the donor erythroid precursors after HSCT for hemoglobinopathies.…”

Section: -3mentioning

confidence: 99%